Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Allsop

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
JAMA Internal Medicine|July 16, 2019
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical TrialNicholas Lintzeris, Anjali Bhardwaj, Llewellyn Mills, et al.
Acta Neuropathologica|October 14, 2009
Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degenerationPenelope G Foulds, Yvonne Davidson, Manjari Mishra, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 5, 2016
Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptideMaria Gregori, Mark Taylor, Elisa Salvati, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 2, 2003
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasmaOmar M A El-Agnaf, Sultan A Salem, Katerina E Paleologou, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 8, 2004
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disordersOmar M A El-Agnaf, Katerina E Paleologou, Brett Greer, et al.
Acta Neuropathologica|October 5, 2011
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotypeYvonne S Davidson, Samantha Raby, Penelope G Foulds, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
JAMA Internal Medicine|July 16, 2019
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical TrialNicholas Lintzeris, Anjali Bhardwaj, Llewellyn Mills, et al.
Acta Neuropathologica|October 14, 2009
Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degenerationPenelope G Foulds, Yvonne Davidson, Manjari Mishra, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 5, 2016
Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptideMaria Gregori, Mark Taylor, Elisa Salvati, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 2, 2003
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasmaOmar M A El-Agnaf, Sultan A Salem, Katerina E Paleologou, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 8, 2004
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disordersOmar M A El-Agnaf, Katerina E Paleologou, Brett Greer, et al.
Acta Neuropathologica|October 5, 2011
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotypeYvonne S Davidson, Samantha Raby, Penelope G Foulds, et al.
Pageof 7